News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UCB, Inc. (UCBJF.PK) and ChemDiv Research Institute Conclude First Phase of Discovery Chemistry Collaboration



6/13/2012 8:48:20 AM

SAN DIEGO, CA and BRUSSELS, BELGIUM and MOSCOW--(Marketwire - June 13, 2012) - UCB and ChemDiv have successfully concluded the first phase of their 2011 collaborative discovery chemistry program executed with ChemDiv's Moscow subsidiary, the ChemDiv Research Institute.

In the course of the collaboration, ChemDiv prepared hundreds of complex and highly targeted medicinal chemical scaffolds, building blocks and templates as part of a complete discovery chemistry solution. The partners' joint steering committee review of progress milestones confirmed the success of the ongoing collaboration, which carries an initial term of 2 years, and can further be extended.

UCB's Benoit Kenda remarked, "UCB had been looking for a partner that has a very strong standing in scaffolds ideation, library preparation and could contribute to UCB's already large and diverse compounds library, in particular in developing special libraries, according to UCB's specifications, and need to inhibit novel Biotargets. We are very happy to have found a partner with ChemDiv which is equally strong in developing novel scaffolds and templates.

Dmitry Kravchenko, CEO of ChemDiv Research Institute, said: "We are pleased that our collaboration with UCB proceeds with continuing success, as acknowledged by both parties. Our success in developing this comprehensive chemistry solution for UCB was enabled by ChemDiv's proprietary Chemistry On Demand™ design and development system, which encompasses over 2B of druggable, target-relevant and validated structure/synthetic space. We are committed to further extending our collaboration with UCB as a long term relationship."

About ChemDiv Research Institute:

ChemDiv and the ChemDiv Research Institute (CDRI) comprise a fully integrated discovery and development CRO based in San Diego and at the ChemRar High Tech Center in Moscow. CDRI collaborates with pharmaceutical and biotech partners by enabling them to accelerate R&D programs to higher value clinical inflection points. ChemDiv and its CDRI subsidiary offer integrated Discovery outSource™ solutions covering the complete range of disciplines, in multiple therapeutic areas (CNS, oncology, inflammation, metabolic, infectious diseases, and others), from discovery research and preclinical development, through accelerated Proof of Concept, and to market registration.


Contacts for media:
Henrik Konarkowski
ChemDiv Research Institute
Email: Email Contact
Phone: +7-495-995-4944


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES